# US 2019/0169234 A1 · Peptide inhibitors of phosphoglycerate mutase and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169234 A1
- Document ID: US20190169234A1
- Status: Published application
- Kind: A1
- Application number: 16/324,424
- Filed: 2017-08-10
- Published: 2019-06-06
- Earliest claimed: 2016-08-11
- Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services; The University of Tokyo; New England Biolabs, Inc.
- Applicants: The University of Tokyo; New England Biolabs, Inc.
- Inventors: James Inglese; Patricia Dranchak; Ryan MacArthur; Hiroaki Suga; Hao Yu; Clotilde Carlow; Zhiru Li
- Web page: https://patentgrep.com/patent/US20190169234A1

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 33/10: Anthelmintics
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.

## Claims

### Claim 1

An isolated cyclic peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1-6, 10-20, or 54-69 wherein the peptide includes an N-terminal ring structure of 7-13 amino acids and a C-terminal linear portion of 1-7 amino acids, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof.

### Claim 2 (depends on 1)

The isolated cyclic peptide of claim 1, wherein the peptide comprises:

### Claim 3 (depends on 1)

The isolated cyclic peptide of claim 1, wherein at least one amino acid is a D-amino acid.

### Claim 4 (depends on 3)

The isolated cyclic peptide of claim 3, wherein the N-terminal amino acid is a D-amino acid.

### Claim 5 (depends on 1)

The isolated cyclic peptide of claim 1, wherein the N-terminal ring structure comprises a thioether linkage.

### Claim 6 (depends on 5)

The isolated cyclic peptide of claim 5, wherein the thioether linkage is between an N-terminal acetyl group and a cysteine residue.

### Claim 7 (depends on 1)

The isolated cyclic peptide of claim 1, wherein the peptide comprises a C-terminal amide.

### Claim 8 (depends on 1)

The isolated cyclic peptide of claim 1, wherein the peptide comprises at least one N-methyl amide in the linear portion of the peptide.

### Claim 9

An isolated peptide comprising the amino acid sequence of SEQ ID NO: 7.

### Claim 10

An isolated peptide comprising any one of the peptides in Tables 2, 6, 8, or 9 or FIGS. 12A, 12B, or 21.

### Claim 11 (depends on 1)

The isolated peptide of claim 1, wherein the peptide inhibits activity of cofactor-independent phosphoglycerate mutase with an IC50 of 100 μM or less.

### Claim 12 (depends on 11)

The isolated peptide of claim 11, wherein the peptide inhibits activity of cofactor-independent phosphoglycerate mutase with an IC50 of 1 pM to 100 μM.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the isolated peptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1)

A method of treating or inhibiting infection with an organism expressing at least one cofactor-independent phosphoglycerate mutase in a subject, comprising administering to the subject an effective amount of the isolated peptide of claim 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject is infected with an organism selected from the group consisting of a nematode, a trypanosome, a helminth, a protozoan parasite, or a bacterium.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject is infected with a nematode, and the nematode comprises one or more of Brugia malayi, Brugia Wuchereria bancrofti, Onchocerca volvulus, Loa loa, Mansonella streptocerca, Mansonella perstans, Mansonella ozzardi, Dirofilaria immitis, Trichinella, Parafilaria bovicola, Onchocerca dermatan, Onchocerca ochengi, Onchocerca dukei, Stenofilaria assamensis, and Parafilaria multipapillosa.

### Claim 17 (depends on 15)

The method of claim 15, wherein the subject is infected with a bacterium and the bacterium comprises one or more of Staphylococcus aureus, Bacillus anthracis, Streptococcus pneumoniae, and Escherichia coli.

### Claim 18 (depends on 14)

The method of claim 14, wherein the peptide is administered orally, intravenously, or topically.

### Claim 19 (depends on 14)

The method of claim 14, further comprising administering one or more of an antiparasitic or antibiotic agent to the subject.

### Claim 20 (depends on 13)

A method of treating or inhibiting infection with an organism expressing at least one cofactor-independent phosphoglycerate mutase in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 13.
